References
- Moku B, Ravindar L, Rakesh KP, et al. The significance of N-methylpicolinamides in the development of anticancer therapeutics: synthesis and structure-activity relationship (SAR) studies[J]. Bioorg Chem. 2019;86:513–537.
- Rakesh KP, Marichannegowda MH, Srivastava S, et al. Combating a master manipulator: staphylococcus aureus immunomodulatory molecules as targets for combinatorial drug discovery. ACS Comb Sci. 2018;20(12):681–693.
- Ravindar L, Bukhari S, Rakesh KP, et al. Aryl fluorosulfate analogues as potent antimicrobial agents: SAR, cytotoxicity and docking studies. Bioorg Chem. 2018;81:107–118.
- Sun Z A total of 139 new drug certificates have been issued under the “major new drug innovation and production” program. [cited 2019 Jul 31]. https://baijiahao.baidu.com/s?id=1640561605505866307&wfr=spider&for=pc
- Wu G, Zhao T, Kang D, et al. Overview of recent strategic advances in medicinal chemistry. J Med Chem. 2019;62(21):9375–9414.
- Zhan P, Pannecouque C, De Clercq E, et al. Anti-HIV drug discovery and development: current innovations and future trends. J Med Chem. 2016;59(7):2849–2878.
- Zhan P, Itoh Y, Suzuki T, et al. Strategies for the discovery of target-specific or isoform-selective modulators. J Med Chem. 2015;58(19):7611–7633.
- Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40(9):1347–1365.
- Chen X, Bai J, Shen F, et al. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin. 2004;25(7):927–931.
- Chong H, Yao X, Zhang C, et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One. 2012;7:3.
- Zhang H, Jin R, Yao C, et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther. 2016;10(13):8.
- Liu H, Long S, Rakesh KP, et al. Structure-activity relationships (SAR) of triazine derivatives: promising antimicrobial agents[J]. Eur J Med Chem. 2000;185:111804-111818.
- Peng P, Chen H, Zhu Y, et al. Structure-based design of 1-heteroaryl-1,3-propanediamine derivatives as a novel series of cc-chemokine receptor 5 antagonists. J Med Chem. 2018;61(21):9621–9636.
- Kang D, Fang Z, Li Z, et al. Design, synthesis, and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles. J Med Chem. 2016;59(17):7991–8007.
- Hu S, Xie G, Zhang D, et al. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Bioorg Med Chem Lett. 2012;22(19):6301–6305.
- Ren X, Pan X, Zhang Z, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013;56(3):879–894.
- Zhang C, Zheng M, Li Y, et al. Design, synthesis, and structure-activity relationship studies of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as a new class of src inhibitors with potent activities in models of triple negative breast cancer. J Med Chem. 2015;58(9):3957–3974.
- Guo D, Li J, Lin H, et al. Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as selective α1A-adrenoceptor antagonists. J Med Chem. 2016;59(20):9489–9502.
- Zhao F, Li J, Chen Y, et al. Design, synthesis, and biological evaluation of indoline and indole derivatives as potent and selective α1A-Adrenoceptor antagonists. J Med Chem. 2016;59(8):3826–3839.
- Xu T, Zhang L, Xu S, et al. Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants. Angew Chem Int Ed Engl. 2013;52(32):8387–8390.
- Du J, Guo J, Kang D, et al. New techniques and strategies in drug discovery. Chinese Chem Lett. 2020. DOI:10.1016/j.cclet.2020.03.028.
- Song S There had been no new drug in the field for 17 years before the domestic alzheimer’s drug GV-971 came to market. https://www.sohu.com/a/351270239_115362. 2011 Nov 2.
- Huang Z Historical breakthrough! China’s cancer drug has been approved for sale in the United States. [cited 2019 Nov 15]. http://news.cctv.com/2019/11/15/ARTIqoxLUAX6W8bDAgGS7YvB191115.shtml
- Liao P, Qiu Y, Mo Y, et al. Selective activation of TWIK-related acid-sensitive K+3 subunit-containing channels is analgesic in rodent models. Sci Transl Med. 2019;11(519):eaaw8434.
- Dai W, Zhang B, Su H, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease [published online ahead of print, 2020 Apr 22]. Science. 2020 Apr 22;eabb4489. doi: 10.1126/science.abb4489.
- Li T. Five ways China must cultivate research integrity. Nature. 2019;575(7784):589–591.
- Woolston C, O’Meara S. PhD students in China report misery and hope. Nature. 2019;575(7784):711–713.